- Home
- SYBT vs SUPN Comparison
SYBT vs SUPN Comparison
Compare SYBT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- SUPN
- Stock Information
- Founded
- SYBT 1904
- SUPN 2005
- Country
- SYBT United States
- SUPN United States
- Employees
- SYBT N/A
- SUPN N/A
- Industry
- SYBT Major Banks
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- SUPN Health Care
- Exchange
- SYBT Nasdaq
- SUPN Nasdaq
- Market Cap
- SYBT 2.3B
- SUPN 2.0B
- IPO Year
- SYBT N/A
- SUPN 2012
- Fundamental
- Price
- SYBT $73.90
- SUPN $36.74
- Analyst Decision
- SYBT Hold
- SUPN Hold
- Analyst Count
- SYBT 3
- SUPN 2
- Target Price
- SYBT $83.67
- SUPN $36.00
- AVG Volume (30 Days)
- SYBT 121.3K
- SUPN 798.3K
- Earning Date
- SYBT 07-23-2025
- SUPN 08-05-2025
- Dividend Yield
- SYBT 1.68%
- SUPN N/A
- EPS Growth
- SYBT 22.18
- SUPN N/A
- EPS
- SYBT 4.35
- SUPN 1.11
- Revenue
- SYBT $364,546,000.00
- SUPN $667,997,000.00
- Revenue This Year
- SYBT $16.37
- SUPN N/A
- Revenue Next Year
- SYBT $5.03
- SUPN $15.74
- P/E Ratio
- SYBT $16.93
- SUPN $33.25
- Revenue Growth
- SYBT 11.32
- SUPN 11.82
- 52 Week Low
- SYBT $53.21
- SUPN $27.05
- 52 Week High
- SYBT $83.67
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- SYBT 37.96
- SUPN 69.55
- Support Level
- SYBT $72.45
- SUPN $32.83
- Resistance Level
- SYBT $79.26
- SUPN $35.92
- Average True Range (ATR)
- SYBT 2.35
- SUPN 1.23
- MACD
- SYBT -0.77
- SUPN 0.22
- Stochastic Oscillator
- SYBT 14.83
- SUPN 88.84
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.